Replimune Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Replimune Group hat ein Gesamteigenkapital von $210.5M und eine Gesamtverschuldung von $47.6M, was einen Verschuldungsgrad von 22.6% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $333.6M bzw. $123.1M.

Wichtige Informationen

22.62%

Verhältnis von Schulden zu Eigenkapital

US$47.63m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$269.14m
Eigenkapital	US$210.54m
Gesamtverbindlichkeiten	US$123.05m
Gesamtvermögen	US$333.59m

Jüngste Berichte zur Finanzlage

Recent updates

Replimune: Multiple Shots On Goal But A High Risk Binary Approaches

Feb 21

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Feb 08

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Aug 01

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Apr 28

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Apr 11

Replimune: A Misunderstood Contender In Oncolytics

Feb 12

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Nov 29

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Nov 23

Replimune: Strong Data In A Highly Differentiated Space

Sep 03

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Aug 16

Replimune: Continuing To Justify The Bear Thesis (For Now)

May 22

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Feb 06

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Jan 23

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Dec 25

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Jul 13

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

Apr 05

A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Jan 06

Replimune secures $200M term loan

Oct 07

Replimune: Recent Developments Strengthen Bull Thesis

Aug 12

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Aug 06

Replimune Group GAAP EPS of -$0.78 misses by $0.15

Aug 04

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Jun 24

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Apr 04

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Dec 16

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: REPLDie kurzfristigen Aktiva des Unternehmens ($280.4M) übersteigen seine kurzfristigen Passiva ($50.1M).

Langfristige Verbindlichkeiten: REPLDie kurzfristigen Vermögenswerte des Unternehmens ($280.4M) übersteigen seine langfristigen Verbindlichkeiten ($73.0M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: REPL über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: REPLDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 22.6% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: REPL hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: REPL verfügt über eine ausreichende Liquiditätsreserve für 1.1 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 26.6% pro Jahr abnimmt.

Entdecken Sie finanziell stabile Unternehmen

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/03/10 04:11
Aktienkurs zum Tagesende	2026/03/10 00:00
Gewinne	2025/12/31
Jährliche Einnahmen	2025/03/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, mit dem dieser Bericht erstellt wurde, sind auf unserer Github-Seite verfügbar. Außerdem bieten wir Anleitungen zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Replimune Group, Inc. wird von 13 Analysten beobachtet. 8 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Clarence Powell	BMO Capital Markets Equity Research
Evan Seigerman	BMO Capital Markets Equity Research
Guyn Kim	BMO Capital Markets Equity Research

Replimune Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Recent updates

Replimune: Multiple Shots On Goal But A High Risk Binary Approaches

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

New minor risk - Financial position

CEO & Director notifies of intention to sell stock

Price target increased by 9.3% to US$12.57

Replimune Group, Inc. Presents Late-Breaking Abstract and Additional Posters on Rp1 At 40Th Annual Meeting of the Society for the Immunotherapy of Cancer (Sitc 2025)

Consensus revenue estimates increase by 28%

Replimune Group, Inc. Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma Prescription Drug User Fee Act (PDUFA) Target Action Date Set for April 10, 2026

Replimune Group, Inc. Highlights Acral Melanoma Data for Rp1 Plus Nivolumab At the ESMO Congress 2025

Replimune Provides Update Following Type A Meeting with FDA

Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman

Price target decreased by 13% to US$4.86

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Replimune Group, Inc., Annual General Meeting, Sep 03, 2025

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Replimune Group, Inc

New major risk - Share price stability

Price target decreased by 48% to US$11.38

Replimune Group, Inc. Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

Replimune Group, Inc. Presents New Analyses from the Ignyte Study of Rp1 Plus Nivolumab in Anti-Pd-1 Failure Melanoma At the 2025 American Society of Clinical Oncology Annual Meeting

Replimune Group, Inc. to Report Q4, 2025 Results on May 22, 2025

New minor risk - Share price stability

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Replimune Group, Inc. Appoints Michael Goller to Its Board of Directors

Replimune: A Misunderstood Contender In Oncolytics

Replimune Group, Inc. Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

New major risk - Shareholder dilution

Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials

Price target increased by 11% to US$18.38

CEO & Director notifies of intention to sell stock

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

New minor risk - Share price stability

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune: Strong Data In A Highly Differentiated Space

Chief Financial Officer recently sold US$91k worth of stock

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Consensus revenue estimates decrease by 50%, EPS upgraded

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Price target increased by 8.2% to US$14.67

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Chief Medical Officer notifies of intention to sell stock

Price target increased by 9.2% to US$14.56

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

New minor risk - Share price stability

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Replimune: Continuing To Justify The Bear Thesis (For Now)

Executive Chairman recently sold US$245k worth of stock

Replimune Group, Inc. Announces Management Changes

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Now 25% undervalued after recent price drop

Price target decreased by 64% to US$17.22

New minor risk - Share price stability

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Chief Medical Officer recently sold US$80k worth of stock

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

New major risk - Revenue and earnings growth

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Chief Business Officer exercised options and sold US$250k worth of stock

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.